Department of Oncology and Pathology, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden.
Medical Oncology, Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Nat Cancer. 2022 Feb;3(2):251-261. doi: 10.1038/s43018-022-00332-x. Epub 2022 Feb 24.
There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical decision support system developed under the umbrella of Cancer Core Europe that creates a unified legal, scientific and technological platform to share and harness next-generation sequencing data. Automating the interpretation and reporting of sequencing results decrease the need for time-consuming manual procedures that are prone to errors. The adoption of an expert-agreed process to systematically link tumor molecular profiles with clinical actions promotes consistent decision-making and structured data capture across the connected centers. The use of information-rich patient reports with interactive content facilitates collaborative discussion of complex cases during virtual molecular tumor board meetings. Overall, streamlined digital systems like the MTBP are crucial to better address the challenges brought by precision oncology and accelerate the use of emerging biomarkers.
在精准肿瘤学护理点，需要高效支持医疗团队工作的系统，这一需求日益增长。在此，我们展示了 Molecular Tumor Board Portal（MTBP）的实现，这是一个在欧洲癌症核心（Cancer Core Europe）的框架下开发的学术临床决策支持系统，它创建了一个统一的法律、科学和技术平台，用于共享和利用下一代测序数据。自动化解释和报告测序结果减少了需要耗时且容易出错的手动操作。采用专家一致同意的流程将肿瘤分子图谱与临床操作系统地联系起来，促进了连接中心之间一致的决策制定和结构化数据采集。使用带有交互内容的信息丰富的患者报告，方便在虚拟分子肿瘤委员会会议期间对复杂病例进行协作讨论。总体而言，像 MTBP 这样的简化数字系统对于更好地应对精准肿瘤学带来的挑战并加速新兴生物标志物的应用至关重要。
